Contribution of platelet antiaggregates in the prevention of complications of atherothrombosis;Apport des antiagregants plaquettaires dans la prevention des complications de l'atherothrombose

Presse Medicale

Volumn 29, Issue 13, 2000, Pages 709-716

  Guilmot, J L ^a,b   Diot, E ^a   Gruel, Y ^b  

^a SERVICE DE DERMATOLOGIE   (France)

^b CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE; DRUG DERIVATIVE;

ARTERY THROMBOSIS; CAROTID ENDARTERECTOMY; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY STENT; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; REVIEW; STROKE; THROMBOCYTE AGGREGATION INHIBITION; ARTICLE; RISK FACTOR; THROMBOSIS; VASCULAR DISEASE;

ASPIRIN; CLINICAL TRIALS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS; TICLOPIDINE; VASCULAR DISEASES;

EID: 0034620977     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994 ; 308:81-106.
2. Dalen JE, Hirsh J. Fith ACCP Proceedings of the American College of Chest Physicians 5th Consensus on Antithrombotic Therapy. Chest 1998 ; 114:S439-769.
3. Patronc C, Coller B, Dalen JE et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998 ; 114:S470-88.
4. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999 ; 138:317-26.
5. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999 : 353:227-31.
6. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous aspirin, both or neither among 19435 patients with acute ischaemic stroke. Lancet 1997 ; 349:1569-81.
7. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-confolled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997 ; 349:1641-9.
8. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 1998 ; 114:S683-98.
9. Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet 1995 ; 346:1509-14.
10. Masurh F, Busch H, Einhaüpl KM. Differences in medical and surgical therapy for stroke preventon between leading experts in north America and western Europe. Stroke 1998 ; 29:339-45.
11. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996 ; 143:1-13.
12. CAPRIE Steering Committee. A randomised, blind trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 ; 348:1329-39.
13. Fitzgerald GA. Dypiridamole. N Engl J Med 1987 ; 316:1247-55.
14. ESPS Group. European stroke prevention study. Stroke 1990 ; 21:1122-30.
15. Bousser MG, Eschwege E, Haguenau M et al. AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of stroke in atnero-thrombotic cerebral ischemia. Stroke 1983 ; 14:5-14.
16. American Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia: endpoint results. Stroke 1985 ; 16:406-15.
17. Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. N Engl J Med 1989 ; 321:501-7.
18. Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989 ; ii:1215-20.
19. Taylor WD, Barnet HJM, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarteredomy: a randomised controlled trial. Lancet 1999 ; 353:2179-84.
20. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988 ; 296:313-6.
21. Steering Committee of the Physicians' Health Study Research. Final report on the aspirin component of the ongoing Physicians' Health Study. Group. The physicians' health study: aspirin for the primary prevention of myocardial infarction. N Engl J Med 1988 ; 318:924-6 et 1989 ; 321:129-35.
22. Steering Committee of the Physicians' Health Study Research. Final report on the aspirin component of the ongoing Physicians' Health Study. Group. The physicians' health study: aspirin for the primary prevention of myocardial infarction. N Engl J Med 1988 ; 318:924-6 et 1989 ; 321:129-35.
23. The Medical Research Council's General Practice in Research Framework. Thrombosis Prevention Trial : randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998 ; 351:233-41.
24. Hensson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1988 ; 351:1755-62.
25. Manson JE, Stampfer MJ, Colditz GA et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991 ; 266:521-7.
26. ISIS-2 (Second International Study of Infarct Survival) Investigators. Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988 ; 2:349-60.
27. Cairns JA, Lewis HD Jr, Meade TW, Sutton GC, Theroux P. Antithrombotic agents n coronary artery disease. Chest 1995 ; 108:S380-400.
28. Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW, Sutton GC. Antithrombotic agents in coronary artery disease. Chest 1998 ; 114:S611-33.
29. Topol EJ, Ferguson JJ, Weisman HF et al. Long term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication. JAMA 1997 ; 278:479-84.
30. Chanu B. Inhibiteurs of GPIIb/IIIa platelet receptors. Arch Mal Cœur Vaiss 1999 ; 92:893-902.
31. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994 ; 330:956-61.
32. Topol EJ, Califf RM, Weisman HF et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six month. The EPIC Investigators. Lancet 1994 ; 343:881-6.
33. Lincoff AM, Califf RM, Anderson KM et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularisation. EPIC Investigators Evaluation of 7E3 in preventing ischemic complications. J Am Coll Cardiol 1997 ; 30:149-56.
34. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997 ; 336:1689-96.
35. The Capture Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997 ; 349:1429-35.
36. Hamm CV, Heeschen C, Goldmann B et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. C7E3 Fab antiplatelet therapy in unstable refractory angina (CAPTURE) Study Investigators. N Engl J Med 1999 ; 340:1623-9.
37. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998 ; 352:87-92.
38. Popma JJ, Weitz J, Bittl JA et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998 ; 114:S728-41.
39. Moussa I, Oetgen M, Roubin G et al. Effectiveness of dopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999 ; 99:2364-6.
40. Jauhar R, Bergman G, Savino S et al. Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting. Am J Cardiol 1999 ; 84:726-8, A8.
41. Janzon L, Bergqvist D, Boberg J et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990 ; 227:301-8.
42. Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999 ; 341:319-27.